GLP-1 seller Hims & Hers Health (NYSE: HIMS) has seen significant volatility in its stock price as of late. Notably, despite seeing a 41% single-day surge in early March, HIMS remains down nearly 10% in 2026. That single-day surge came as Hims and Novo Nordisk A/S (NYSE: NVO), the maker of Wegovy, announced a new collaboration.
Now, Hims no longer needs to sell copycat versions of Novo’s weight loss and diabetes drugs. Novo will allow Hims to sell branded versions of its Ozempic and Wegovy injectables, as well as the Wegovy pill. Novo also dropped its lawsuit against Hims. With Novo’s revenues moving in the wrong direction, Hims will act as a sales channel for the firm.
